Xeris Pharmaceuticals, Inc. (XERS)

NASDAQ: XERS · IEX Real-Time Price · USD
2.26
0.26 (13.00%)
At close: May 27, 2022 4:00 PM
2.15
-0.11 (-4.87%)
After-hours:May 27, 2022 5:08 PM EDT
Market Cap306.30M
Revenue (ttm)63.47M
Net Income (ttm)-138.03M
Shares Out135.53M
EPS (ttm)-1.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,540,765
Open2.04
Previous Close2.00
Day's Range2.02 - 2.29
52-Week Range1.25 - 4.98
Beta1.81
AnalystsBuy
Price Target6.38 (+182.3%)
Earnings Daten/a

About XERS

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's synd...

IndustryPharmaceuticals
IPO DateJun 21, 2018
Employees294
Stock ExchangeNASDAQ
Ticker SymbolXERS
Full Company Profile

Financial Performance

In 2021, XERS's revenue was $49.59 million, an increase of 142.67% compared to the previous year's $20.44 million. Losses were -$122.73 million, 34.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for XERS stock is "Buy." The 12-month stock price forecast is 6.38, which is an increase of 182.30% from the latest price.

Price Target
$6.38
(182.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing'...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...

2 weeks ago - Business Wire

Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...

2 weeks ago - Business Wire

Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...

3 weeks ago - Business Wire

Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...

2 months ago - Business Wire

Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...

2 months ago - Business Wire

Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (“Xeris” or “the Company”) (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in...

2 months ago - Business Wire

Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...

2 months ago - Business Wire

Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and ga...

3 months ago - Business Wire

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...

3 months ago - Business Wire

Xeris Biopharma Eyes High End Of FY21 Sales Outlook

Xeris Biopharma Holdings Inc (NASDAQ: XERS) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately 55% growth from 2020. The company held ...

4 months ago - Benzinga

Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) (“Xeris” or the “Company”), a biopharmaceutical company developing and commercializing unique therapies for patient populations in...

4 months ago - Business Wire

PANTHERx Rare Selected By Xeris Pharmaceuticals To Distribute Recorlev

PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a n...

4 months ago - Benzinga

PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endo...

PITTSBURGH, Jan. 13, 2022 /PRNewswire/ -- PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive ...

4 months ago - PRNewsWire

Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and ga...

4 months ago - Business Wire

Xeris Biopharma Enters Into Agreement for $30 Million Private Placement

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) (“Xeris” or the “Company”), a biopharmaceutical company developing and commercializing unique therapies for patient populations in...

4 months ago - Business Wire

Moderna's on the Rise, but This Small Biotech Is the Nasdaq's Big Winner on New Year's Eve

Find out what's moving markets on the last day of the year.

Other symbols:MRNA
4 months ago - The Motley Fool

Here's Why Xeris Biopharma Stock Is Jumping Today

The FDA approved Recorlev for the treatment of endogenous Cushing's syndrome.

4 months ago - The Motley Fool

XERS Stock Pops on Huge FDA News. Here's What to Know.

The FDA approved Xeris' Recorlev drug for certain adult patients with Cushing's syndrome, sending XERS stock higher. The post XERS Stock Pops on Huge FDA News.

4 months ago - InvestorPlace

Why Xeris Biopharma Shares Are Rising Today

Xeris Biopharma Holdings Inc (NASDAQ: XERS) is trading higher Friday morning after the company announced U.S. Food and Drug Administration approval of Recorlev for the treatment of endogenous hypercorti...

4 months ago - Benzinga

Xeris Biopharma soars on premarket leading volume after FDA approval of Cushing's syndrome treatment

Shares of Xeris Biopharma Holdings Inc. XERS, -3.19% shot up 24.3% on heavy volume in premarket trading Friday toward a five-month high, after the biopharmaceutical company said its Recorlev has been ap...

4 months ago - Market Watch

Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercort...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...

4 months ago - Business Wire

5 Beaten Down Biotech Stocks That Could Bounce Big In 2022

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in pro...

Other symbols:ACADALBORCKTTHRX
5 months ago - Benzinga

Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...

5 months ago - Business Wire

4 Penny Stocks To Buy For Under $5 Before 2022

You can buy these penny stocks for under $5 but are they worth the risk? The post 4 Penny Stocks To Buy For Under $5 Before 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...

Other symbols:ATNFFWBIPTPI
5 months ago - PennyStocks